

UK NEQAS CD34+ Stem Cell Enumeration Programme Findings

Liam WhitbyCentre Manager



Disclaimer

- The information in this presentation was compiled for informational purposes only.
- All policies and procedures herein should serve as a guideline, which you
 can use to create your own policies and procedures.
- You may choose to customize your own operations and believe that these slides may be helpful for this endeavor.
- Any and all information contained herein is not intended to constitute legal advice.
- You should not take, or refrain from taking action based on this content.
- I assume no liability in connection with this presentation, including any information, methods or safety suggestions contained herein.
- This presentation cannot be assumed to contain every acceptable safety and compliance procedure or that additional procedures might not be appropriate under the circumstances.
- Read this disclaimer at your own risk
- Over 18s only

UK NEQAS History

- In 1962, 50 leading laboratories were provided with an identical blood sample
- Returned haemoglobins ranged from 120 to 170 g/L
- This highlighted the need for interlaboratory quality assessment
- From this the foundations of UK NEQAS were then laid in 1969 by Professor Tom Whitehead in Clinical Chemistry & Dr. Mitchell Lewis in Haematology

UKNEQAS: Objectives

The mission of UK NEQAS is to ensure the provision of an appropriate, responsive & high standard of EQA

To provide laboratories with:

- an assessment of intra and inter laboratory performance
- relative performance of available kits and methods
- factors associated with good and poor performance
- a tool to monitor and improve the between-laboratory agreement

The primary role of UK NEQAS is educational



CD34⁺ Stem Cell Enumeration

- Routinely performed to optimize timing of peripheral stem cell collections
- EQA important as test is a go/no go test
- ISHAGE protocol most widely employed
- Currently 292/315 (93%) participants in the UK NEQAS CD34+ stem cell enumeration programme indicate that this is their chosen protocol



Trial Operation


- CD34⁺ stem cell samples procured from consented patients undergoing stem cell harvest
- Samples stabilised and pooled to produce blood samples of differing CD34⁺ stem cell counts
- Samples suitable for use with whole blood lysis techniques and sequential gating strategies on all platforms

Stability of Samples

UK NEQAS International Quality Expertise

Stabilised PNH Granulocytes

Developed biological control material for internal & external quality assurance with Dr S Richards, HMDS, Leeds





Trial Operation


- 2 samples issued
- 3 week trial window
- CD34⁺ enumeration performed (Single platform ISHAGE is recommended)
- Results are returned via the web site www.ukneqasli.co.uk
- Report produced



ISHAGE Protocol

 Sutherland D.R, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34⁺ cell determination by flow cytometry. Journal of Hematotherapy 1996; 5: 213-226

CD34 Gating – ISHAGE Protocol




- Boolean gating strategy
- Uses Forward and Side scatter characteristics and antigen expression

D.R. Sutherland Toronto, Canada




Plot 1






Plot 2



- Events from P1 displayed on SSC/CD34 plot
- P2 includes
 CD34+ events





Plot 3



- CD45⁺ and CD34⁺ events from P1 and P2 displayed on SSC/CD45 (P3)
- Shows cells with characteristic low SSC and dim CD45 fluorescence

Plot 4 And Plot 5 UK NEGAS International Quality Expertise






- Events from P1, P2 and P3 are displayed on a SSC/FSC plot to confirm the selected events fall into a generic 'lymph-blast' region – P4
- P4 is set precisely to include lymphocytes from plot 1(P5) as shown in plot 5
- Any cells falling outside region P4
 excluded from final calculation









- Ungated data displayed on a CD34/CD45 histogram
- Assists in positioning of CD45 dim gate in plot 3
- Also useful for identifying bead population for single platform

Plot 7 And Plot 8







- These plots show viable cells
- Important in removing dead cells present particularly in thawed samples
- When using stabilised cells either increase this gate to include all cells or remove this stage completely

UK NEQAS International Quality Expertise

Gating Strategy Study

- Study carried out in response to poor performance caused by incorrect gating strategy
- Results published 2012 Whitby A, Whitby L, Fletcher M, Reilly JT, Sutherland DR, Keeney M, Barnett D. ISHAGE protocol: Are we doing it correctly? Cytometry Part B 2012; 82B: 9-17
 - Second most downloaded paper in Cytometry Part B for the year 2013


UK NEQAS International Quality Expertise

Gating Strategy Study

- Labs were asked to submit their dot plots (103/255 submitted)
- These were compared to the stated protocol used and whether it was correctly or incorrectly implemented
- 81% who returned dot plots stated that they were using ISHAGE


UK NEQAS

Results of ISHAGE Gating Strategy Analysis




UK NEQAS

Breakdown Of Incorrect Application



- Omission of P5 region in P1 region - 75%
- Omission of Low SSC/CD45 dim plot (plot 3) - 14%
- Wrong parameter 2%
- Wrong antibody 2%
- Non-use of ISHAGE gating strategy - 5%
- Non-use of any previously published gating strategy - 2%






Missing Gate

 No R5 gate in region 1 showing position of lymphocytes to satisfy R4 lymphocyte check

UK NEQAS International Quality Expertise

Wrong Parameter



CD34/CD45 plot used to gate on CD45 dim instead of the correct SSC/CD45



Participant Survey 2015

Survey Rationale

- Dedicated questionnaire issued to all participating centres (n=1587) to survey current and planned changes in flow cytometric techniques
- Questionnaire featured several sections, each related to different aspects of flow cytometry
- Issued to 310 participants in CD34⁺ stem cell enumeration programme
- 148 returned results (48%) for the CD34⁺ stem cell enumeration section were downloaded and analysed

UK NEQAS
International Quality Expertise

Best Practice CD34

- According to the BCSH guidelines (1999)
 - Use ISHAGE protocol
 - Use single platform
 - Use electronic pipette
 - Use reverse pipetting
 - Count a minimum 50000 events or 100 CD34+ events

Recommendations	Number of Laboratories (n=148)
ISHAGE	
Single Platform	
Electronic Pipette	
Reverse Pipetting	
50000 Events/100 CD34+ events	
*Pipette Serviced Annually	
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	
Electronic Pipette	
Reverse Pipetting	
50000 Events/100 CD34+ events	
*Pipette Serviced Annually	
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	123 (83%)
Electronic Pipette	
Reverse Pipetting	
50000 Events/100 CD34+ events	
*Pipette Serviced Annually	
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	123 (83%)
Electronic Pipette	16 (11%)
Reverse Pipetting	
50000 Events/100 CD34+ events	
*Pipette Serviced Annually	
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	123 (83%)
Electronic Pipette	16 (11%)
Reverse Pipetting	13 (9%)
50000 Events/100 CD34+ events	
*Pipette Serviced Annually	
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	123 (83%)
Electronic Pipette	16 (11%)
Reverse Pipetting	13 (9%)
50000 Events/100 CD34+ events	12 (8%)
*Pipette Serviced Annually	
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	123 (83%)
Electronic Pipette	16 (11%)
Reverse Pipetting	13 (9%)
50000 Events/100 CD34+ events	12 (8%)
*Pipette Serviced Annually	11 (7%)
*Flow Cytometer Serviced Annually	

^{*}Good laboratory practice

Recommendations	Number of Laboratories (n=148)
ISHAGE	134 (91%)
Single Platform	123 (83%)
Electronic Pipette	16 (11%)
Reverse Pipetting	13 (9%)
50000 Events/100 CD34+ events	12 (8%)
*Pipette Serviced Annually	11 (7%)
*Flow Cytometer Serviced Annually	11 (7%)

^{*}Good laboratory practice

UK NEQAS

Participant Survey Results — CD34 Methodology

- Events counted ranged from
 - 10000 (n=1) to 1000000 (n=3) total events
 - 50 (n=3) to 500 (n=3) CD34⁺ (BCSH Guidelines recommend minimum of 100 CD34⁺ cells or 50000 events)
- Limits for harvest varied from 5 to 64 CD34+ cells/uL
- Reporting units are cells/uL, cellsx10⁶/L and cellsx10⁹/L



Conclusion

- Survey data shows only 7% laboratories testing are performing the assay correctly
- Previous publication shows only 58% laboratories applying ISHAGE gating strategy correctly
- These figures combined give a theoretical worst case of only 4% of centres performing the assay correctly
- Urgent need for laboratories to ensure correct performance of CD34+ stem cell enumeration assay
- Imperative that laboratories ensure the correct application of the ISHAGE gating strategy



Summary- So What!

- Team GB British Cycling team were once described as a laughing stock or also-rans
- Sir Dave Brailsford transformed British Cycling
 - 22 gold medals at the last 3 Olympic games
 - 4 Tour de France winners in the last 5 years
- Used the theory of marginal gains
 - Break a process into small segments and make 1% improvement in each area
 - These marginal gains accumulate
- "They're tiny things but if you clump them together it makes a big difference" – Sir David Brailsford, 2012

UK NEQAS International Quality Expertise

What Should Labs Do?

- There are options available to ensure correct methodologies are in place
- Refer to publications
 - Whitby A, Whitby L, Fletcher M, Reilly JT, Sutherland DR, Keeney M,
 Barnett D. ISHAGE protocol: Are we doing it correctly? Cytometry Part B 2012; 82B: 9-17
 - D. Barnett, G. Janossy, A. Lubenko, E. Matutes, A. Newland, J. T. Reilly. Guideline for the flow cytometric enumeration of CD34⁺ haematopoietic stem cells. Clin. Lab. Haem 1999; 21: 301-308
 - Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34⁺ cell determination by flow cytometry. Journal of Hematotherapy 1996; 5: 213-226
- UK NEQAS is here to help.
 - Tel +44 (0) 114 267 3600
 - Email alison.whitby@ukneqasli.co.uk